More on CADL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-166.7% Growth)
- Ratings (9.2 Score)

Upcoming Events

- Earnings (8/19/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Candel Therapeutics (NQ:CADL)
Delayed: 8.31 +0.32 (4.01%)
Prev. Close $7.99  
Open$8.25 
52 Wk High$ 
52 Wk Low$ 
Day High$8.59 
Day Low$7.93 
P/E N/A  
EPS$ 
Volume8,197,173 

Friends, Peers and Foes (?): TRIN (more...)

Jun 16, 2026 04:24 PM Form 8-K Candel Therapeutics, For: Jun 12
Jun 2, 2026 08:05 AM Candel publishes phase 3 prostate cancer trial data in Lancet Oncology
Jun 2, 2026 08:05 AM Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
Jun 1, 2026 04:05 PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026 03:22 PM Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities
May 15, 2026 04:19 PM Form 8-K Candel Therapeutics, For: May 15
May 15, 2026 04:05 PM Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial
May 15, 2026 04:05 PM Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
May 15, 2026 08:09 AM Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP
May 14, 2026 08:31 AM Form 10-Q Candel Therapeutics, For: Mar 31
View All Articles

Entities mentioned with CADL

View All Entities